Liminatus Pharma, Inc. (LIMN) stock
LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$2.81+0.13 (+4.85%)
Close on Nov 19, 2026Market cap $188.72MP/E –Yield –
Liminatus Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Liminatus Pharma's R&D Expenses for the twelve months ending Dec 31, 2024 was $2.69M. For fiscal 2024 it was $2.69M.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.69M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $600.00K | -16.0% |
| Q1 FY2026 | Mar 31, 2026 | $400.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $357.07K | – |
| Q2 FY2024 | Jun 30, 2024 | $714.13K | – |
See a number that looks wrong?